The safety and efficacy of controlled-release and
immediate-release pregabalin are comparable for the treatment of fibromyalgia.
According to a recent study published in Journal Expert
Review of Neurotherapeutics, PGB-CR (Pregabalin controlled-release) shows
similar safety and efficacy as PGB-IR (Pregabalin immediate-release).
Fibromyalgia (FM) is a condition that involves fatigue, cognitive impairment, musculoskeletal
pain and sleep disturbances. Due to these problems, this disease dramatically
affects the occupational, social and personal life. The pregabalin is an
anticonvulsant and antidepressants; milnacipran and duloxetine are the FDA
approved drugs for FM treatment.
Expert Review of Neurotherapeutics
Controlled-release Pregabalin in the treatment of fibromyalgia.
Alessandra Alciati et al.
Comments (0)